Legal Representation
Attorney
Perry Gattegno
USPTO Deadlines
Next Deadline
1249 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-03-28)
Due Date
March 28, 2029
Grace Period Ends
September 28, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
10 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 28, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Mar 28, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jan 10, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 10, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 21, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 6, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 5, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 25, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Feb 24, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 24, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 036
Providing venture capital, development capital, private equity and investment funding; Venture capital services, namely, providing financing to emerging and start-up companies
First Use Anywhere:
20200900
First Use in Commerce:
20200900
Class 042
Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Biochemical research and development; Consulting services in the field of pharmacogenetics; Pharmaceutical research and development; Scientific research and development; Vaccine research and development
First Use Anywhere:
20200900
First Use in Commerce:
20200900
Additional Information
Design Mark
The mark consists of the blue word FUSION in capitalized text, with the orange word BIOVENTURE to its right, oriented vertically, all above the blue text FOSUN PHARMA US INNOVATION HUB, which is next to a small blue triangle. The O in FUSION is displayed around a stylized flame comprising an orange semi-circular shape at the bottom, a set of three gradient orange and yellow vertical lines in the middle, and a grid of fifteen orange dots at the top. The areas shown in white are for background only and are not claimed as part of the mark.
Color Claim
The color(s) blue, orange and yellow is/are claimed as a feature of the mark.
Classification
International Classes
036
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOVENTURE" AND "PHARMA US INNOVATION HUB"